000880:KRXHanwha Corporation Analysis
Data as of 2026-03-17 - not real-time
₩121,900.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
The stock trades at 121,900 KRW, comfortably above the 20‑day SMA (126,745) and 50‑day SMA (115,800), indicating a bullish price structure. It sits near the identified support at 111,000 KRW and well below the 148,500 KRW resistance, giving a cushion for upside. Technical momentum is mixed: RSI at 49 suggests neutral momentum, while the MACD histogram is negative and the signal line is bearish, warning of short‑term weakness. Volume has been trending downward, which may limit the strength of any rally. Nonetheless, the 30‑day volatility is high (≈93%) and the computed beta of 0.67 points to lower systematic risk than the market.
Fundamentally, the company appears markedly cheap: a forward P/E of 7.3 versus an industry average of 29.3, and a DCF‑derived fair value of roughly 618,000 KRW imply about a 20% upside from current levels. Revenue is expanding at a robust 45.6% annual rate, and the modest dividend yield of 0.89% is supported by a low payout ratio of 5.9%, suggesting sustainability. However, the balance sheet is heavily leveraged (debt‑to‑equity >130%) and profit margins remain thin, tempering the upside narrative. Overall, the blend of attractive valuation, strong top‑line growth, and a defensible dividend makes the stock a compelling buy for medium‑ to long‑term horizons, while short‑term traders may prefer to wait for clearer technical confirmation.
Fundamentally, the company appears markedly cheap: a forward P/E of 7.3 versus an industry average of 29.3, and a DCF‑derived fair value of roughly 618,000 KRW imply about a 20% upside from current levels. Revenue is expanding at a robust 45.6% annual rate, and the modest dividend yield of 0.89% is supported by a low payout ratio of 5.9%, suggesting sustainability. However, the balance sheet is heavily leveraged (debt‑to‑equity >130%) and profit margins remain thin, tempering the upside narrative. Overall, the blend of attractive valuation, strong top‑line growth, and a defensible dividend makes the stock a compelling buy for medium‑ to long‑term horizons, while short‑term traders may prefer to wait for clearer technical confirmation.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price above 20‑day and 50‑day SMAs
- Negative MACD histogram indicating bearish momentum
- Decreasing volume reducing short‑term support
Medium Term
1–3 yearsPositive
Model confidence: 8/10
Key Factors
- Forward P/E far below industry average
- DCF fair value suggesting ~20% upside
- Strong revenue growth and sustainable dividend
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Diversified conglomerate reducing sector concentration risk
- Continued top‑line growth prospects across multiple segments
- Low dividend payout ratio supporting long‑term cash flow
Key Metrics & Analysis
Financial Health
Revenue Growth45.60%
Profit Margin1.74%
P/E Ratio7.3
ROE8.91%
ROA1.21%
Debt/Equity133.08
Op. Cash Flow₩9598.8B
Free Cash Flow₩1434.6B
Industry P/E29.3
Technical Analysis
TrendBullish
RSI49.0
Support₩111,000.00
Resistance₩148,500.00
MA 20₩126,745.00
MA 50₩115,800.00
MA 200₩93,600.50
MACDBearish
VolumeDecreasing
Fear & Greed Index79.45
Valuation
Fair Value₩617,781.10
Target Price₩146,400.00
Upside/Downside20.10%
GradeUndervalued
TypeBlend
Dividend Yield0.89%
Risk Assessment
Beta0.67
Volatility92.85%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.